As Boston-based Rhythm Pharmaceuticals moves its lead obesity treatment into a second Phase III trial, the company was bolstered by the publication of longer-term data from its Phase II study of setmelanotide in Nature Medicine.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
Roche’s hopes of Tecentriq catching rival medicines from Merck and Bristol-Myers Squibb were dealt a blow after the immunotherapy failed a key combination trial.
Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder.
Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for the multiple sclerosis treatment ozanimod.
British scientists have developed a far more accurate blood test to diagnose peanut allergy, offering a better way to monitor a significant food hazard.
A Finnish study suggests a regular sauna habit is associated with a lower risk of strokes.
Bristol-Myers dropped two Phase III clinical trials of the IDO1 inhibitor acquired from Flexus Biosciences.
Allergan Plc announced positive results from a second Phase III trial for a 50-milligram dose of the company’s drug for acute migraine, reproducing results from the previous clinical study.
International scientists identified 44 genetic variants that can increase the risk of developing major depression and found that all humans carry at least some of them.
Boehringer Ingelheim presented the family-owned pharmaceutical company’s latest pipeline updates at an R&D press conference entitled ‘Transcending Disease Boundaries’ at its global headquarters in Ingelheim, Germany.
The concept of combining two immunotherapy drugs to fight lung cancer suffered a fresh blow from the failure of an AstraZeneca clinical study.
An arthritis drug developed by Eli Lilly and Co. and Incyte Corp. should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted.
Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
Gene-editing technologies that alter mosquitoes’ DNA could prove critical in the fight against malaria, Bill Gates said, and ethical concerns should not block progress in such gene-modifying research.
Eli Lilly unveiled final data from the MONARCH 3 study that helped the drug garner FDA approval in February 2018 for the treatment of some breast cancer patients.
Janssen Pharmaceuticals has teamed up with Bristol-Myers Squibb to drive BMS-986177, a Factor XIa (FXIa) inhibitor, into Phase II development for the study of secondary stroke prevention and major thrombotic conditions.
A late-stage trial of Amgen Inc.’s Aimovig found that the experimental drug reduced episodic migraines by at least half in 30 percent of patients who had failed up to four previous treatments.
Merck & Co.’s immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly diagnosed patients with advanced non-small cell lung cancer in a highly anticipated study.
CRISPR Therapeutics is ready to begin treating patients in Europe using the company’s CRISPR gene-editing tool. The plan is to treat patients with beta thalassemia, a blood disorder that decreases the production of hemoglobin, the iron-containing protein in red blood cells that carries oxygen.
An Independent Monitoring Committee recommended that Pfizer halt the Phase III ATLAS trial of Inlyta (axitinib) because it was not proving effective.